Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 4
Submit an article Journal homepage
3,576
Views
61
CrossRef citations to date
0
Altmetric
Original Research

Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma

Cristian CapassoLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Mari HirvinenLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Mariangela GarofaloLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland;Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Via Pansini, Naples, Italy
,
Dmitrii RomaniukLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Lukasz KurykLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Teea SarvelaLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Andrea VitaleDepartment of Movement Sciences and Wellness (DiSMEB), University of Naples Parthenope, Via Medina 40, Naples, Italy, CEINGE-Biotecnologie Avanzate, Via G. Salvatore 486, Naples, Italy
,
Maxim AntopolskyDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Aniket MagarkarDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Tapani ViitalaDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Teemu SuutariDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Alex BunkerDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Marjo YliperttulaDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland
,
Arto UrttiDivision of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, Finland;School of Pharmacy, University of Eastern Finland, Yliopistonranta 1, Kuopio, Finland
&
Vincenzo CerulloLaboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences and Center for Drug Research, University of Helsinki, Viikinkaari 5, Helsinki, FinlandCorrespondence[email protected]
 show all
Article: e1105429 | Received 14 Jul 2015, Accepted 04 Oct 2015, Published online: 08 Apr 2016

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Hajar Rajayi, Parsova Tavasolian, Alaleh Rezalotfi & Marzieh Ebrahimi. (2019) Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche. International Reviews of Immunology 38:6, pages 267-283.
Read now
Victor Cervera-Carrascon, Riikka Havunen & Akseli Hemminki. (2019) Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. Expert Opinion on Biological Therapy 19:5, pages 443-455.
Read now
Lukasz Kuryk, Anne-Sophie W. Møller & Magnus Jaderberg. (2019) Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. OncoImmunology 8:2.
Read now
Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now
S. Feola, C. Capasso, M. Fusciello, B. Martins, S. Tähtinen, M. Medeot, S. Carpi, F. Frascaro, E. Ylosmäki, K. Peltonen, L. Pastore & V. Cerullo. (2018) Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. OncoImmunology 7:8.
Read now
Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri Tähtinen, Lucio Pastore, Alex Bunker & Vincenzo Cerullo. (2017) A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma. OncoImmunology 6:9.
Read now

Articles from other publishers (55)

Mariangela Garofalo, Magdalena Wieczorek, Ines Anders, Monika Staniszewska, Michal Lazniewski, Marta Prygiel, Aleksandra Anna Zasada, Teresa Szczepińska, Dariusz Plewczynski, Stefano Salmaso, Paolo Caliceti, Vincenzo Cerullo, Ramon Alemany, Beate Rinner, Katarzyna Pancer & Lukasz Kuryk. (2023) Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model. Frontiers in Oncology 13.
Crossref
Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, Mikko Mäyränpää, Jukka Partanen, Satu Koskela, Jarno Honkanen, Jussi Halonen, Lukasz Kuryk, Maria Rescigno, Mikaela Grönholm, Rui M. Branca, Janne Lehtiö & Vincenzo Cerullo. (2023) Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors. Nature Communications 14:1.
Crossref
Firas Hamdan, Manlio FuscielloVincenzo Cerullo. (2023) Personalizing Oncolytic Virotherapy. Human Gene Therapy 34:17-18, pages 870-877.
Crossref
Lulu Jin & Zhengwei Mao. (2023) Living virus‐based nanohybrids for biomedical applications. WIREs Nanomedicine and Nanobiotechnology.
Crossref
Renato Brito Baleeiro, Peng Liu, Louisa S Chard Dunmall, Carmela Di Gioia, Ai Nagano, Lauren Cutmore, Jun Wang, Claude Chelala, Lydon Wainaina Nyambura, Peter Walden, Nicholas Lemoine & Yaohe Wang. (2023) Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. Journal for ImmunoTherapy of Cancer 11:8, pages e007336.
Crossref
Xianwang Wang, Yihua Shen, Xingxia Wan, Xiaoqing Hu, Wen-Qi Cai, Zijun Wu, Qiang Xin, Xiaoqing Liu, Jingang Gui, Hong-Yi Xin & Hong-Wu Xin. (2023) Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. Journal of Translational Medicine 21:1.
Crossref
Momeneh Ghanaat, Hami Kaboosi, Babak Negahdari, Esmail Fattahi & Ziba Veisi Malekshahi. (2023) Heterologous Prime-boost Vaccination Using Adenovirus and Albumin Nanoparticles as Carriers for Human Papillomavirus 16 E7 Epitope. Current Pharmaceutical Biotechnology 24:9, pages 1195-1203.
Crossref
Chenchao Feng, Peng Tan, Guangjun Nie & Motao Zhu. (2023) Biomimetic and bioinspired nano‐platforms for cancer vaccine development. Exploration 3:3.
Crossref
Nasser Hashemi Goradel, Mahnaz Nemati, Azam Bakhshandeh, Arash Arashkia & Babak Negahdari. (2023) Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen. International Immunopharmacology 117, pages 109887.
Crossref
Christianne Groeneveldt, Jasper van den Ende & Nadine van Montfoort. (2023) Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?. Cytokine & Growth Factor Reviews 70, pages 1-12.
Crossref
Zhijian Huang, Hongen Guo, Lin Lin, Shixiong Li, Yong Yang, Yuanyuan Han, Weiwei Huang & Jialiang Yang. (2023) Application of oncolytic virus in tumor therapy. Journal of Medical Virology 95:4.
Crossref
Lukasz Kuryk & Anne-Sophie W. Møller. (2023) Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models. Molecular Therapy - Oncolytics 28, pages 158-170.
Crossref
Lorella Tripodi, Emanuele Sasso, Sara Feola, Ludovica Coluccino, Maria Vitale, Guido Leoni, Barbara Szomolay, Lucio Pastore & Vincenzo Cerullo. (2023) Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers 15:4, pages 1297.
Crossref
Ali Zarezadeh Mehrabadi, Fatemeh Roozbahani, Reza Ranjbar, Mahdieh Farzanehpour, Alireza Shahriary, Ruhollah Dorostkar & Hadi Esmaeili Gouvarchin Ghaleh. (2022) Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses. World Journal of Surgical Oncology 20:1.
Crossref
Harun Achmad, Yousif Saleh Ibrahim, Muataz Mohammed Al-Taee, Gamal A. Gabr, Muhammad Waheed Riaz, Shadia Hamoud Alshahrani, Andrés Alexis Ramírez-Coronel, Abduladheem Turki Jalil, Hendrik Setia Budi, Windi Sawitri, Malyutina Elena Stanislavovna & Jitendra Gupta. (2022) Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting. International Immunopharmacology 113, pages 109434.
Crossref
Petteri Parkkila, Kai Härkönen, Petra Ilvonen, Saara Laitinen & Tapani Viitala. (2022) Protein A/G-based surface plasmon resonance biosensor for regenerable antibody-mediated capture and analysis of nanoparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects 654, pages 130015.
Crossref
Man Yao, Simo Cheng, Xiaofeng Zhai, Hetong Zhao, Jing Hong, Xiaoyan Li, Yongbin Meng & Wei Chen. (2022) Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis. Applied Bionics and Biomechanics 2022, pages 1-9.
Crossref
S. Feola, S. Russo, E. Ylösmäki & V. Cerullo. (2022) Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment. Pharmacology & Therapeutics 236, pages 108103.
Crossref
Sara Feola, Salvatore Russo, Beatriz Martins, Alessandra Lopes, Gaëlle Vandermeulen, Vinciane Fluhler, Camilla De Giorgi, Manlio Fusciello, Sari Pesonen, Erkko Ylösmäki, Gabriella Antignani, Jacopo Chiaro, Firas Hamdan, Michaela Feodoroff, Mikaela Grönholm & Vincenzo Cerullo. (2022) Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. Frontiers in Immunology 13.
Crossref
Sara Feola, Jacopo Chiaro, Beatriz Martins, Salvatore Russo, Manlio Fusciello, Erkko Ylösmäki, Chiara Bonini, Eliana Ruggiero, Firas Hamdan, Michaela Feodoroff, Gabriella Antignani, Tapani Viitala, Sari Pesonen, Mikaela Grönholm, Rui MM Branca, Janne Lehtiö & Vincenzo Cerullo. (2022) A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. eLife 11.
Crossref
Nasser Hashemi Goradel, Babak Negahdari, Nasir Mohajel, Ziba Veisi Malekshahi, Maryam Mashhadi Abolghasem Shirazi & Arash Arashkia. (2021) Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model. International Immunopharmacology 101, pages 108298.
Crossref
Jacopo Chiaro, Henna H.E. Kasanen, Thomas Whalley, Cristian Capasso, Mikaela Grönholm, Sara Feola, Karita Peltonen, Firas Hamdan, Micaela Hernberg, Siru Mäkelä, Hanna Karhapää, Paul E. Brown, Beatriz Martins, Manlio Fusciello, Erkko O. Ylösmäki, Dario Greco, Anna S. Kreutzman, Satu Mustjoki, Barbara Szomolay & Vincenzo Cerullo. (2021) Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. Cancer Immunology Research 9:8, pages 981-993.
Crossref
Karita Peltonen, Sara Feola, Husen M. Umer, Jacopo Chiaro, Georgios Mermelekas, Erkko Ylösmäki, Sari Pesonen, Rui M. M. Branca, Janne Lehtiö & Vincenzo Cerullo. (2021) Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy. Cancers 13:14, pages 3408.
Crossref
Erkko Ylösmäki, Manlio Fusciello, Beatriz Martins, Sara Feola, Firas Hamdan, Jacopo Chiaro, Leena Ylösmäki, Matthew J Vaughan, Tapani Viitala, Prasad S Kulkarni & Vincenzo Cerullo. (2021) Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin. Journal for ImmunoTherapy of Cancer 9:7, pages e002707.
Crossref
Mariangela Garofalo, Federica Bellato, Salvatore Magliocca, Alessio Malfanti, Lukasz Kuryk, Beate Rinner, Samuele Negro, Stefano Salmaso, Paolo Caliceti & Francesca Mastrotto. (2021) Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells. Pharmaceutics 13:7, pages 949.
Crossref
Martí Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino & Ramon Alemany. (2021) Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus. Clinical Cancer Research 27:11, pages 2979-2988.
Crossref
Lorella Tripodi, Maria Vitale, Vincenzo Cerullo & Lucio Pastore. (2021) Oncolytic Adenoviruses for Cancer Therapy. International Journal of Molecular Sciences 22:5, pages 2517.
Crossref
Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jäger, Sari Pesonen & Vincenzo Cerullo. (2021) Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Molecular Therapy - Oncolytics 20, pages 459-469.
Crossref
Siddhartha Sood, Rahul Jayachandiran & Siyaram Pandey. (2021) Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies 20, pages 153473542199007.
Crossref
Manlio Fusciello, Erkko Ylösmäki & Vincenzo Cerullo. 2021. Bio-Nanomedicine for Cancer Therapy. Bio-Nanomedicine for Cancer Therapy 317 325 .
Lukasz Kuryk, Laura Bertinato, Monika Staniszewska, Katarzyna Pancer, Magdalena Wieczorek, Stefano Salmaso, Paolo Caliceti & Mariangela Garofalo. (2020) From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers 12:10, pages 3057.
Crossref
Erkko Ylösmäki & Vincenzo Cerullo. (2020) Design and application of oncolytic viruses for cancer immunotherapy. Current Opinion in Biotechnology 65, pages 25-36.
Crossref
Emanuele Sasso, Anna Morena D’Alise, Nicola Zambrano, Elisa Scarselli, Antonella Folgori & Alfredo Nicosia. (2020) New viral vectors for infectious diseases and cancer. Seminars in Immunology 50, pages 101430.
Crossref
Selas T.F. Bots & Rob C. Hoeben. (2020) Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?. International Journal of Molecular Sciences 21:14, pages 4821.
Crossref
Siri Tähtinen, Sara Feola, Cristian Capasso, Netta Laustio, Christianne Groeneveldt, Erkko O. Ylösmäki, Leena Ylösmäki, Beatriz Martins, Manlio Fusciello, Marta Medeot, Maria Tagliamonte, Jacopo Chiaro, Firas Hamdan, Karita Peltonen, Tuuli Ranki, Luigi Buonaguro & Vincenzo Cerullo. (2020) Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Cancer Research 80:12, pages 2575-2585.
Crossref
Manlio Fusciello, Flavia Fontana, Siri Tähtinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Ylösmäki, Erkko Ylösmäki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, Hélder A. Santos & Vincenzo Cerullo. (2019) Artificially cloaked viral nanovaccine for cancer immunotherapy. Nature Communications 10:1.
Crossref
Svetlana Atasheva, Jia Yao & Dmitry M. Shayakhmetov. (2019) Innate immunity to adenovirus: lessons from mice. FEBS Letters 593:24, pages 3461-3483.
Crossref
Eric A. Weaver. (2019) Dose Effects of Recombinant Adenovirus Immunization in Rodents. Vaccines 7:4, pages 144.
Crossref
Lukasz Kuryk, Anne‐Sophie W. Møller & Magnus Jaderberg. (2019) Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. Journal of Medical Virology 91:9, pages 1702-1706.
Crossref
Mohammad Krayem, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem & Dirk Van Gestel. (2019) The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers 11:8, pages 1093.
Crossref
Nasser Hashemi Goradel, Nasir Mohajel, Ziba Veisi Malekshahi, Samira Jahangiri, Masoud Najafi, Bagher Farhood, Keywan Mortezaee, Babak Negahdari & Arash Arashkia. (2018) Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. Journal of Cellular Physiology 234:6, pages 8636-8646.
Crossref
Andrea Patrizia Falanga, Vincenzo Cerullo, Maria Marzano, Sara Feola, Giorgia Oliviero, Gennaro Piccialli & Nicola Borbone. (2019) Peptide Nucleic Acid-Functionalized Adenoviral Vectors Targeting G-Quadruplexes in the P1 Promoter of Bcl-2 Proto-Oncogene: A New Tool for Gene Modulation in Anticancer Therapy. Bioconjugate Chemistry 30:3, pages 572-582.
Crossref
Lukasz Kuryk, Anne-Sophie Møller, Antti Vuolanto, Sari Pesonen, Mariangela Garofalo, Vincenzo Cerullo & Magnus Jaderberg. (2019) Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks. International Journal of Molecular Sciences 20:3, pages 621.
Crossref
M. Garofalo, A. Villa, N. Rizzi, L. Kuryk, B. Rinner, V. Cerullo, M. Yliperttula, V. Mazzaferro & P. Ciana. (2019) Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. Journal of Controlled Release 294, pages 165-175.
Crossref
Justyna Struzik & Lidia Szulc-Dąbrowska. (2018) NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses—Therapeutic Perspectives. Cancers 10:11, pages 426.
Crossref
Lukasz Kuryk, Anne-Sophie W. Møller, Mariangela Garofalo, Vincenzo Cerullo, Sari Pesonen, Ramon Alemany & Magnus Jaderberg. (2018) Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. Journal of Medical Virology 90:10, pages 1669-1673.
Crossref
Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylösmäki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala & Vincenzo Cerullo. (2018) Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. Molecular Therapy 26:9, pages 2315-2325.
Crossref
M. Garofalo, H. Saari, P. Somersalo, D. Crescenti, L. Kuryk, L. Aksela, C. Capasso, M. Madetoja, K. Koskinen, T. Oksanen, A. Mäkitie, M. Jalasvuori, V. Cerullo, P. Ciana & M. Yliperttula. (2018) Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. Journal of Controlled Release 283, pages 223-234.
Crossref
Alexander Baker, Carmen Aguirre-Hernández, Gunnel Halldén & Alan Parker. (2018) Designer Oncolytic Adenovirus: Coming of Age. Cancers 10:6, pages 201.
Crossref
Nikolas Tim Martin & John Cameron Bell. (2018) Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Molecular Therapy 26:6, pages 1414-1422.
Crossref
Dayananda Kasala, Soo-Hwan Lee, Jin Woo Hong, Joung-Woo Choi, Kihoon Nam, Yoon Ho Chung, Sung Wan Kim & Chae-Ok Yun. (2017) Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus. Biomaterials 145, pages 207-222.
Crossref
Carlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, Rafael Moreno, Marcel Arias-Badia, Jana de Sostoa, Carl H. June & Ramon Alemany. (2017) Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. Cancer Research 77:8, pages 2052-2063.
Crossref
Francesca Maria Bosisio & Joost J. van den Oord. (2017) Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Archiv 470:4, pages 357-369.
Crossref
Amelia Aitken, Dominic Roy & Marie-Claude Bourgeois-Daigneault. (2017) Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines 5:4, pages 3.
Crossref
Lukasz Kuryk, Elina Haavisto, Mariangela Garofalo, Cristian Capasso, Mari Hirvinen, Sari Pesonen, Tuuli Ranki, Lotta Vassilev & Vincenzo Cerullo. (2016) Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. International Journal of Cancer 139:8, pages 1883-1893.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.